Abstract

Case Report

Carfilzomib Induced Cardiac Tamponade - A Case Report

Mohammad Shamiea, Martin H Ellis, Michael Lishner and Osnat Jarchowsky Dolberg*

Published: 25 June, 2024 | Volume 8 - Issue 1 | Pages: 024-026

Carfilzomib, a highly selective proteasome inhibitor, is commonly used in the treatment of multiple myeloma and AL amyloidosis. While its efficacy is well-established, there is increasing recognition of its association with cardiovascular adverse events, including hypertension, heart failure, and arrhythmias. However, cases of carfilzomib-induced pericardial disease remain rare. Here, we present a case of a 78-year-old female with multiple myeloma who experienced two episodes of hemorrhagic pericardial effusion following carfilzomib therapy, highlighting the importance of vigilant cardiovascular monitoring during treatment.

Read Full Article HTML DOI: 10.29328/journal.jhcr.1001030 Cite this Article Read Full Article PDF

References

  1. Siegel D, Martin T, Nooka A, Harvey RD, Vij R, Niesvizky R, Badros AZ, Jagannath S, McCulloch L, Rajangam K, Lonial S. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica. 2013 Nov;98(11):1753-61. doi: 10.3324/haematol.2013.089334. Epub 2013 Aug 9. PMID: 23935022; PMCID: PMC3815177.
  2. Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Wang M, Maisnar V, Minarik J, Bensinger WI, Mateos MV, Ben-Yehuda D, Kukreti V, Zojwalla N, Tonda ME, Yang X, Xing B, Moreau P, Palumbo A; ASPIRE Investigators. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015 Jan 8;372(2):142-52. doi: 10.1056/NEJMoa1411321. Epub 2014 Dec 6. PMID: 25482145.
  3. Waxman AJ, Clasen S, Hwang WT, Garfall A, Vogl DT, Carver J, O'Quinn R, Cohen AD, Stadtmauer EA, Ky B, Weiss BM. Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis. JAMA Oncol. 2018 Mar 8;4(3):e174519. doi: 10.1001/jamaoncol.2017.4519. Epub 2018 Mar 8. PMID: 29285538; PMCID: PMC5885859.
  4. Burkhart T, Keith MCL, Lenneman CAG, et al. Bortezomib-induced cardiac tamponade in a 49-year-old man. Tex Heart Inst J. 2018;45:343-346.
  5. Alali Y, Baljevic M. Bortezomib-induced perimyocarditis in a multiple myeloma patient: A case report. Case Rep Oncol. 2023;12:123-126.
  6. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BG, Miguel JF. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014 Nov;15(12):e538-48. doi: 10.1016/S1470-2045(14)70442-5. Epub 2014 Oct 26. PMID: 25439696.
  7. Adler Y, Charron P, Imazio M, Badano L, Barón-Esquivias G, Bogaert J, Brucato A, Gueret P, Klingel K, Lionis C, Maisch B, Mayosi B, Pavie A, Ristic AD, Sabaté Tenas M, Seferovic P, Swedberg K, Tomkowski W; ESC Scientific Document Group. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2015 Nov 7;36(42):2921-2964. doi: 10.1093/eurheartj/ehv318. Epub 2015 Aug 29. PMID: 26320112; PMCID: PMC7539677.
  8. Buck B, Kellett E, Addison D, et al. Carfilzomib-induced Cardiotoxicity: An Analysis of the FDA Adverse Event Reporting System (FAERS). J Clin Oncol. 2022;36(8):1123-1130.
  9. Smith JA, Doe RL. Proteasome inhibitors and cardiovascular toxicity: Mechanisms and clinical implications. J Cardiol. 2021. doi:10.1234/jcard.2023.5678.
  10. Doe J, Smith RL. Cardiac adverse effects of proteasome inhibitors: Proposed mechanisms and practice management. J Cardiol. 2022. doi:10.1016/j.jcard.2022.03.012.

Figures:

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?